* CRL questions SPARKLE endpoint analysis; re-read rejected *Ascelia disputes both points; expresses confidence * Type A meeting next; outcomes range widely
ANNONS
The CRL's stated grounds
In the CRL (Complete Response Letter), the FDA states that SPARKLE failed its co-primary endpoints on the initial read, and rejects the subsequent re-evaluation on two grounds: i.) a risk that new readers were influenced by prior knowledge of the images/results; and ii) a scoring scope limited to T1-weighted images, which the FDA says cannot show added value over standard-of-care imaging (which includes non-T1 sequences).
Ascelia's response
The company disputes both points. It states the second readers had no prior knowledge of the images or earlier results, directly countering the FDA's bias concern. On imaging scope, the FDA's comment concerns what was scored in the re-read, while Ascelia's statement concerns what was acquired in the trial (confirming T1, T2 and DWI sequences were all collected), a distinction the company appears confident resolves the concern once clarified with the FDA. Ascelia also states its re-read approach was discussed with the FDA pre-submission, though the CRL itself does not address this either way. On product documentation, management seems confident and expects resolution in the near term. Overall, Ascelia maintains that SPARKLE was an adequate and well-controlled pivotal study providing a robust basis for evaluating Orviglance, while remaining confident the product documentation issues can be resolved in the near term.
What's next?
Ascelia maintains that it will submit a briefing package and request an expedited FDA Type A meeting, which, if granted, is typically held within 30 days of the request. Outcomes could range from a relatively quick resolution based on clarification alone, to a further re-read scoring the full set of acquired sequences rather than T1 only, or, in the worst case, a new pivotal trial with fresh patient data, a materially tougher and likely unfeasible scenario given the funding and timelines required. While the FDA has historically applied a stringent standard when reviewing CRL responses and may ultimately require a more extensive path forward, management's confidence suggests it expects one of the faster outcomes. Valuation remains suspended until there is more clarity.
